Table 4 Factors associated with virological success
Univariate model | Multivariate model | |||
|---|---|---|---|---|
Hazard Ratio (95% confidence interval) | p-value | Hazard Ratio (95% confidence interval) | p-value | |
Region | 0.07 | < 0.01 | ||
Eastern Europe | 1 | 1 | ||
Western/Southern Europe | 0.99(0.77–1.27) | 1.03 (0.75–1.41) | ||
Latin America | 1.29(0.97–1.73) | 1.42 (1.04–1.94) | ||
Age, years | 0.59 | 0.87 | ||
30 vs 20 | 1.13(084–1.52) | 1.12 (0.83–1.51) | ||
40 vs 20 | 1.24(0.76–2.02) | 1.22 (0.74–2.01) | ||
50 vs 20 | 1.26(0.80–2.00) | 1.28 (0.80–2.06) | ||
Male | 1.01(0.81–1.27) | 0.91 | 0.93 (0.73–1.18) | 0.53 |
Disseminated TB | 0.90(0.73–1.12) | 0.34 | 0.86 (0.69–1.07) | 0.17 |
IDU | 1.07(0.85–1.34) | 0.58 | 1.16 (0.87–1.55) | 0.30 |
TB susceptibility | 0.79 | 0.84 | ||
No MDR vs MDR | 1.07(0.65–1.75) | 1.05(0.62–1.78) | ||
No Resistance test vs MDR | 1.04(0.63–1.72) | 0.98(0.58–1.66) | ||
Rifamicin | 1.25(0.79–1.97) | 0.33 | ||
Efavirenz | 1.05(0.84–1.30) | 0.68 | 0.97(0.76–1.22) | 0.77 |
ART naïve | 1.11(0.90–1.37) | 0.33 | 1.09(0.86–1.39) | 0.44 |
CD4+ at TB diagnosis (cells/mm3) | 0.48 | 0.41 | ||
100 vs 50 | 0.99(0.90–1.08) | 0.99(0.90–1.10) | ||
200 vs 50 | 0.96(0.79–1.16) | 0.98(0.79–1.20) | ||
350 vs 50 | 0.91(0.73–1.14) | 0.92(0.73–1.17) |